Vivo Bio Tech has informed that the Board of Directors of the Company at their meeting held on Monday, July 13, 2026, transacted the following business: Considered and approved the Unaudited Standalone & Consolidated Financial Results of the Company for the First quarter ended June 30, 2026. A copy of the signed Results along with Limited Review Report issued by the Statutory Auditors, P. Murali & Co., Chartered Accountants, are enclosed as Annexure-A. The meeting commenced at 07:00 pm and concluded at 07:30 pm.
The above information is a part of company’s filings submitted to BSE.